创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

胡川, 宋钰珺, 高会乐. 肿瘤微环境响应性纳米递药系统用于肿瘤免疫治疗的研究进展[J]. 药学进展, 2022, 46(7): 485-494.
引用本文: 胡川, 宋钰珺, 高会乐. 肿瘤微环境响应性纳米递药系统用于肿瘤免疫治疗的研究进展[J]. 药学进展, 2022, 46(7): 485-494.
HU Chuan, SONG Yujun, GAO Huile. Advances in Research on Tumor Microenvironment-responsive Nano Drug Delivery Systems for Tumor Immunotherapy[J]. Progress in Pharmaceutical Sciences, 2022, 46(7): 485-494.
Citation: HU Chuan, SONG Yujun, GAO Huile. Advances in Research on Tumor Microenvironment-responsive Nano Drug Delivery Systems for Tumor Immunotherapy[J]. Progress in Pharmaceutical Sciences, 2022, 46(7): 485-494.

肿瘤微环境响应性纳米递药系统用于肿瘤免疫治疗的研究进展

Advances in Research on Tumor Microenvironment-responsive Nano Drug Delivery Systems for Tumor Immunotherapy

  • 摘要: 在过去的几十年里,癌症免疫治疗取得了巨大的进步,但不尽如人意的患者应答率及潜在的免疫相关不良事件仍是临床上的主要挑战。纳米递药系统在癌症治疗方面具有独特的优势。基于肿瘤微环境缺氧、弱酸性、蛋白酶异常表达等特点,研究者们进一步设计了刺激响应性纳米递药系统,其已被广泛研究用于提高抗肿瘤免疫应答的效果和减少免疫相关的副作用。介绍了肿瘤微环境响应性纳米递药系统用于肿瘤免疫治疗的研究进展,并讨论了该类递药系统的应用前景和面临的挑战。

     

    Abstract: Great progress on cancer immunotherapy has been made in the past few decades, but unsatisfactory patient response rate and potential immune related adverse events are still the main clinical challenges. Nano drugs delivery systems (NDDSs) have unique advantages in tumor treatment. Based on the characteristics of tumor microenvironment(TME) such as hypoxia, weak acidity and abnormal expression of protease, researchers have designed stimulus-responsive NDDSs, which have been widely studied to improve the effectiveness of anti-tumor immune response and to reduce immune-related side effects. This article introduces the advances in research on tumor microenvironment-responsive NDDSs used for tumor immunotherapy, and discusses the application prospect and challenges of this type of drug delivery systems.

     

/

返回文章
返回